Emeryville, CA, United States of America

Karin Jooss

This inventor holds 10 USPTO granted patents and 25 published patent applications and 1 EPO patent. Top assignees: Gritstone Bio, Inc., Gritstone Oncology, Inc.. Active years: 2022-2026.

USPTO Granted Patents = 10 (Patent Applications = 25)

% Patents Active = 100.0

EPO Patents = 1 (Patent Applications = 33)

Average Co-Inventor Count = 4.5

ph-index = 1

Company Filing History:

Gritstone Oncology, Inc.

patents

Years Active: 2022-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653883 - ALPHAVIRUS NEOANTIGEN VECTORS AND INTERFERON INHIBITORS (2026-06-16),

2. 12643949 - MULTI-SPECIFIC ANTIBODIES AND METHODS OF USE (2026-06-02),

3. 12630637 - ANTIGEN-BINDING PROTEINS AND RELATED METHODS OF USE (2026-05-19),

4. 12616746 - INFECTIOUS DISEASE ANTIGENS AND VACCINES (2026-05-05),

5. 12109257 - Alphavirus neoantigen vectors (2024-10-08),

6. 12098383 - Modified adenoviruses (2024-09-24),

7. 11771747 - Multiepitope vaccine cassettes (2023-10-03),

8. 11591619 - Modified adenoviruses (2023-02-28),

9. 11510973 - Alphavirus antigen vectors (2022-11-29),

10. 11504421 - Alphavirus neoantigen vectors (2022-11-22),

Title: The Innovative Contributions of Karin Jooss

Introduction

Karin Jooss is a prominent inventor based in Emeryville, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of novel vaccine technologies. With a total of 10 patents to his name, Jooss has established himself as a key figure in his area of expertise.

Latest Patents

Karin Jooss's latest patents include groundbreaking work on alphavirus neoantigen vectors. These vectors incorporate neoantigen-encoding nucleic acid sequences derived from tumors, providing innovative methods for vaccine development. Additionally, he has developed modified adenoviruses, which consist of compositions that include nucleotides, cells, and methods associated with their use as vaccines. His research also explores viral vectors utilizing a TET promoter system, along with methods for producing viruses with these characteristics.

Career Highlights

Jooss is currently associated with Gritstone Bio, Inc., where he continues to push the boundaries of vaccine research. His work has been instrumental in advancing therapeutic options for cancer and infectious diseases. His innovative approaches have garnered attention in the scientific community, contributing to the ongoing evolution of vaccine technology.

Collaborations

Karin Jooss has collaborated with notable colleagues, including Ciaran Daniel Scallan and Leonid Gitlin. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in the field.

Conclusion

Karin Jooss's contributions to biotechnology and vaccine development are noteworthy. His innovative patents and collaborative efforts position him as a leading inventor in his field. The impact of his work continues to resonate within the scientific community, paving the way for future advancements.